Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)

Phase 3 Recruiting 140 enrolled Fundacion Clinic per a la Recerca Biomédica

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a national multicenter, randomized clinical trial to evaluate the the efficacy and safety of DP administration in patients on the liver transplant waiting list to reduce intraoperative red blood cell concentrate transfusion.

Timeline

Start: 2025-11-25
Primary completion: 2026-12
Completion: 2027-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Darbepoetin alfa	Protein / enzyme biologic	1.5 ug/kg	Subcutaneous

Indications

No indication recorded.